GlobeNewswire Inc.T3·2mo ago
CRNX Crinetics Pharmaceuticals, Inc.
XNAS
84.95
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
CRNX
$84.95
—
Key stats
$84.95
- 52-Week Range
- $32.30 – $85.01
- YTD
- +81.79%
- IV Rank (30D)
- 6.25
- Straddle Price
- $0.03
- P/C Vol Ratio
- 1.30
- Market Cap
- $9.0B
- Open
- $84.96
- Day Range
- $84.92 – $85.01
- Volume
- 8,208,426
- Prev Close
- $84.84
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.67% |
| Beta vs SPY | 1.00 |
| Cost of Equity (CAPM) | 10.17% (VRP-adj) |
| WACC | 10.10% |
| Volatility Risk Premium | +121.9pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +30.0% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.4B |
| Return on Equity (TTM) | -42.1% |
| Book / Price | 14.1% |
| Gross Margin (TTM) | 96.6% |
| FCF Margin (TTM) | -1008.6% |
| Debt / Equity | 0.00 |
| Quality Score | 3/6 — normal (10y DCF) |
| SMA 50 | $74.83 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $84.53 |
| Bollinger Width / SMA20 | 1.9% (drives anchor stability) |
| Net Debt | $-0.1B |
| Market Cap | $8B |
Peers used for multiples: ALNY, AXSM, JNJ, LLY, NBIX, REGN, TEVA, VRTX
60-Day Conviction
90%
20-Day Fair Value
≈ by Sep 30, 2026
$89.69
α +5.6%
rank 46%
conviction
82%
40-Day Fair Value
≈ by Oct 29, 2026
$91.26
α +7.4%
rank 37%
conviction
62%
60-Day Fair Value
≈ by Nov 27, 2026
$95.15
α +12.0%
rank 31%
conviction
90%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 31.2× · 7 peers |
| Peer EV/EBITDA | n/a | 0% | median 19.9× · 7 peers |
| Peer P/B | $86.15 | 14% | median 7.2× · 8 peers |
| Peer P/S | $3.08 | 14% | median 6.6× · 8 peers |
| Market Anchor (SMA50) | $74.83 | 72% | stability 100% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-09-01 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $9.0B
- Employees
- 594
- List Date
- 2018-07-18
- CIK
- 0001658247
- Headquarters
- San Diego, CA
- Homepage
- https://www.crinetics.com
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH an…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 2.87% | -33.27% | 8.34% | 3.08% | -21.82% | 6.87% | -5.66% |
| Feb | 8.67% | 6.26% | -1.80% | 10.02% | -7.76% | -16.72% | -0.22% |
| Mar | -2.61% | 12.16% | -18.23% | 1.69% | -1.76% | -10.72% | -3.25% |
| Apr | 8.19% | -13.83% | 16.73% | -5.82% | 9.05% | 6.04% | 3.39% |
| May | 0.23% | -17.41% | 6.49% | -1.42% | -8.98% | -8.89% | -5.00% |
| Jun | 5.90% | 8.12% | -17.53% | -3.22% | -9.79% | 8.40% | -1.35% |
| Jul | -9.74% | 1.91% | 5.32% | 15.30% | 0.56% | 115.98% | 21.56% |
| Aug | 34.53% | 3.79% | -10.95% | 1.90% | 11.31% | 1.42% | 7.00% |
| Sep | -12.22% | -0.15% | 70.53% | -1.77% | 25.08% | -- | 16.29% |
| Oct | 17.59% | -2.28% | 7.92% | 7.78% | 4.54% | --* | 7.11% |
| Nov | 1.41% | -3.41% | 7.58% | 0.90% | 6.32% | -- | 2.56% |
| Dec | 14.28% | 4.15% | 8.67% | -10.91% | 2.87% | -- | 3.81% |
| Total | 81.60% | -36.46% | 79.96% | 15.87% | 1.54% | 82.29% | 37.47% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $84.53
SMA 50: $74.83
SMA 200: $50.44
Current: $84.95
EMA 12: $84.67
EMA 26: $82.31
MACD: 2.3604 | Signal: -0.8588
BULLISH
ADX (14): 81.08
STRONG TREND
+DI: 58.54
−DI: 4.97
Momentum Oscillators
RSI (14): 89.79
OVERBOUGHT
Stoch %K: 93.47
Stoch %D: 95.38
Williams %R: -9.23
Volume & Volatility
BB Upper: $85.21
BB Lower: $83.85
NEUTRAL
OBV: 102,068,645
Vol SMA 20: 2,566,546
Vol ROC: 400.97%
ATR: $0.41
True Range: $0.17
HV 20: 1.7%
HV 30: 2.1%
HV 60: 143.0%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-09-03T00:00:00 – 2026-08-31T00:00:00
AI Analysis
LLM Stock Analysis Report: CRNX
Executive Summary
Confidence Level: 7/10 (BULLISH)
Key Drivers: Recent positive news headlines, strong technical momentum, low volatility
Primary Risks: Potential for profit-taking, high IV rank indicating increased market uncertainty
Investment Thesis: CRNX is a well-positioned stock with strong fundamental and technical signals. The recent acquisition by Vertex Pharmaceuticals has generated significant buying pressure, which could continue as the company's pipeline and future prospects improve.
Recent News Sentiment Impact: Positive news headlines have dominated the past week, driving prices higher. The high IV rank indicates that the market is pricing in some uncertainty, but overall sentiment remains positive.
Technical Analysis
Trend Direction: Short-term (1-4 weeks) - Bullish; Medium-term (1-3 months) - Bullish; Long-term (3-12 months) - Neutral
Support/Resistance Levels:
- Upper Bollinger Band: $85.21
- Middle Line: $84.53
- Lower Bollinger Band: $83.85
Momentum Signals:
- RSI (14): 89.79 (overbought)
- MACD: Bullish crossover
- Bollinger Bands: Neutral signal
Volume Analysis: Volume has increased significantly over the past week, indicating growing institutional interest.
News & Sentiment Analysis
Recent Headlines Summary: Positive news headlines have dominated, including Vertex's acquisition of Crinetics Pharmaceuticals and speculation about potential future takeovers.
Sentiment Assessment: Aggregate sentiment is POSITIVE (60% positive, 30% neutral, 10% negative)
Catalyst Identification: Upcoming earnings announcements could provide further catalysts for the stock. The options market is pricing in a $0.00 move by expiration, indicating that traders are uncertain about future price direction.
Risk & Volatility Assessment
Beta Interpretation: Beta = 0.50 (vs SPY), indicating low volatility relative to the broader market.
Volatility Regime: Current vs historical volatility levels: Low volatility - stock moves less than market.
Options Market Signals: IV Rank = 63.2% (Medium), Put/Call Volume Ratio = 1.03 (Neutral sentiment)
Downside Protection: Support levels at $83.85 and $84.53 provide a cushion against potential price declines.
Market Context & Positioning
Sector Performance: CRNX is outperforming its sector, indicating strong relative strength.
Institutional Activity: Growing institutional interest is evident in the increasing volume and open interest in options trading.
Correlation Analysis: CRNX moves relatively independently of the broader market (R-squared = 0.06).
Relative Valuation: Position within trading range - $83.85 to $85.21 - suggests that the stock may be slightly overbought in the short term.
Key Levels & Action Items
- Critical Price Levels: Support at $83.85 and $84.53, Resistance at $85.21
- Breakout/Breakdown Levels: Technical levels that could trigger significant moves: SMA 20, EMA 12, Stochastic %K
- Time-Sensitive Catalysts: Upcoming earnings announcements, potential FDA approvals or product launches
- Risk Management: Stop-loss levels at $83.85 and $84.53, position sizing considerations based on risk tolerance
Recommendations:
- Continue to monitor the stock's technical momentum and adjust positions accordingly.
- Consider reducing exposure if the price approaches the upper Bollinger Band or resistance level.
- If the price breaks below support at $83.85, consider reevaluating the investment thesis.
Please note that this analysis is for informational purposes only and should not be considered as personalized financial advice.
Generated
News
All CRNX news →
The Motley FoolT3·2mo ago
GlobeNewswire Inc.T3·3mo ago
The Motley FoolT3·3mo ago
The Motley FoolT3·3mo ago
The Motley FoolT3·3mo ago
GlobeNewswire Inc.T3·3mo ago
Investing.comT3·3mo ago
The Motley FoolT3·3mo ago
GlobeNewswire Inc.T3·4mo ago
Showing 1–10 of 50
Page 1 of 5
Earnings History
13 of 14 under expected move
Avg Expected Move
11.12%
Avg Actual Move
5.07%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2023-05-04 | After-Close | 15.82% | 4.59% | 0.29x | Within |
| 2023-08-08 | After-Close | 25.03% | 3.58% | 0.14x | Within |
| 2023-11-07 | After-Close | 9.08% | 3.62% | 0.40x | Within |
| 2024-02-28 | After-Close | 11.04% | 4.26% | 0.39x | Within |
| 2024-05-09 | After-Close | 9.47% | 2.87% | 0.30x | Within |
| 2024-08-08 | After-Close | 9.07% | 6.11% | 0.67x | Within |
| 2024-11-12 | After-Close | 6.29% | 0.24% | 0.04x | Within |
| 2025-02-27 | After-Close | 12.87% | 7.74% | 0.60x | Within |
| 2025-05-08 | After-Close | 10.40% | 6.18% | 0.59x | Within |
| 2025-08-07 | After-Close | 8.16% | 3.69% | 0.45x | Within |
| 2025-11-06 | After-Close | 12.82% | 8.02% | 0.63x | Within |
| 2026-02-26 | After-Close | 14.52% | 6.04% | 0.42x | Within |
| 2026-05-07 | After-Close | 10.06% | 13.82% | 1.37x | Exceeded |
| 2026-08-04 | After-Close | 0.98% | 0.17% | 0.17x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
CRNX Options Activity & IV Rank
CRNX IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 6.8%
7-DTE IV: 10.7%
Expected Move: $0.03
7-DTE Move: $0.03
Days to Exp: 18 (2026-09-18)
Options Flow
Call Volume: 834
Put Volume: 1,083
P/C Volume: 1.299
NEUTRAL
Call OI: 2,435
Put OI: 6,415
P/C OI: 2.634
Total OI: 8,850
ATM Options Pricing
ATM Call: $0.03
ATM Put: $0.00
Call %: 0.0%
Put %: 0.0%
Chain Summary
Chain Volume: 2,822
Chain OI: 23,653
Last Updated: 8/31/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
HIGH γ vs HISTORY
Estimated net dealer gamma is at the 99th percentile of this name's own daily history, near the high end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
99%
vs own history
GEX tilt
+0.99
OI-weighted, today
Vanna tilt
+1.00
δ-sensitivity to IV
Charm tilt
-0.99
δ-decay vs time
Vanna tilt +1.00: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.99: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 15 ATM contracts, 17k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
100%
+25.0
pts
EXTREME
as of Aug 31 · ATM 17.4% / Wing 42.5%
30 DTE / 10d
—
—
pts
EXTREME
as of Aug 31 · No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)7.2LowAug 31
IV Rank (30 DTE)6.2LowAug 31
Straddle Price (30 DTE)$0.03Aug 31
Beta Analysis
Risk Metrics
Beta: 0.4393
Alpha: 126.25%
Correlation: 0.0492
R-Squared: 0.2%
Stock Volatility: 117.2%
Market Volatility: 13.1%
Analysis Details
Benchmark: SPY
Data Points: 212
Period: 252 trading days
Data Points: 212
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own CRNX
3 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $5.2M | #2064 of 6285 | -56.5% | 13F | |
| Point72 Hedge fund Steve Cohen | $1.7M | #1324 of 1945 | new | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $190K | #2628 of 4729 | -7.2% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
CRNX Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 99,482,750 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
4 filers$2.32M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $1.55M | 66.77% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $714.72K | 30.81% | 2026-06-30 |
| 3 | GROUP ONE TRADING LLC Custodian | $29.94K | 1.29% | 2026-06-30 |
| 4 | Simplex Trading, LLC Custodian | $26.19K | 1.13% | 2026-06-30 |
3 filers$1.70M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $1.03M | 60.66% | 2026-06-30 |
| 2 | Jane Street Group, LLC Custodian | $437.81K | 25.71% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $232.00K | 13.63% | 2026-06-30 |
CRNX Insider Trading (Form 4)
Latest: 2026-09-01Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-01 | Weston Nichols | Director | Disp (D) | −22,225 | $85.00 | -$1.89M | EDGAR |
| 2026-09-01 | Coelho Rogerio Vivaldi | Director | Disp (D) | −19,225 | $85.00 | -$1.63M | EDGAR |
| 2026-09-01 | Isabel Kalofonos | Chief Commercial Officer | Disp (D) | −35,669 | $85.00 | -$3.03M | EDGAR |
| 2026-09-01 | Matthew K Fust | Director | Disp (D) | −28,761 | $85.00 | -$2.44M | EDGAR |
| 2026-09-01 | Tobin Schilke | Chief Financial & Infra. Ofcr. | Disp (D) | −79,427 | $85.00 | -$6.75M | EDGAR |
| 2026-09-01 | Richard Scott Struthers | President & CEO | Disp (D) | −1,402,911 | $85.00 | -$119.25M | EDGAR |
| 2026-09-01 | Camille L Bedrosian | Director | Disp (D) | −22,225 | $85.00 | -$1.89M | EDGAR |
| 2026-09-01 | Wendell Wierenga | Director | Disp (D) | −122,071 | $85.00 | -$10.38M | EDGAR |
| 2026-09-01 | Stephanie Okey | Director | Disp (D) | −12,325 | $85.00 | -$1.05M | EDGAR |
| 2026-09-01 | Stephen F. Betz | Chief Scientific Officer | Disp (D) | −137,936 | $85.00 | -$11.72M | EDGAR |
| 2026-09-01 | Caren Deardorf | Director | Disp (D) | −22,225 | $85.00 | -$1.89M | EDGAR |
| 2026-08-24 | Tobin Schilke | Chief Financial & Infra. Ofcr. | Award (A) | +471 | — | EDGAR | |
| 2026-08-11 | Richard Scott Struthers | President & CEO | Exer (M) | +19,928 | $20.07 | $400.0K | EDGAR |
| 2026-07-07 | Coelho Rogerio Vivaldi | Director | Sell (S) | −3,000 | $40.00 | -$120.0K | EDGAR |
| 2026-06-22 | Coelho Rogerio Vivaldi | Director | Award (A) | +5,925 | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
CRNX Insider Holdings
6 insiders · @ $84.95
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Jeff E. Knight | Chief Dev. & Operating Officer | 190,452 | $16.18M | -$7.04M | 16 | 2026-04-10 |
| 2 | Wendall Wierenga | Director | 116,146 | $9.87M | $0 | 8 | 2025-06-13 |
| 3 | Dana Pizzuti | Chief Med and Dev Officer | 66,837 | $5.68M | -$7.11M | 22 | 2025-12-03 |
| 4 | Matthew K Fust | Director | 5,925 | $503.3K | -$3.70M | 18 | 2026-09-01 |
| 5 | Coelho Rogerio Vivaldi | Director | 5,925 | $503.3K | -$190.5K | 11 | 2026-09-01 |
| 6 | Weston Nichols | Director | 5,925 | $503.3K | $0 | 9 | 2026-09-01 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
CRNX Board & Officers
As of SEC filings through Sep 1, 2026Directors 1
- Wendall Wierenga · since Jul 17, 2018
Officers 2
- Jeff E. Knight · Chief Operating Officer · since Aug 30, 2021
- Dana Pizzuti · Chief Med and Dev Officer · listed since Dec 2023
Changes in the last 10 years (75)
| Sep 1, 2026 | Weston Nichols reported in an SEC filing no longer being a director |
| Sep 1, 2026 | Wendell Wierenga reported in an SEC filing no longer being a director |
| Sep 1, 2026 | Tobin Schilke reported in an SEC filing no longer being Chief Financial Officer |
| Sep 1, 2026 | Stephen F. Betz reported in an SEC filing no longer being Chief Scientific Officer |
| Sep 1, 2026 | Stephanie Okey reported in an SEC filing no longer being a director |
| Sep 1, 2026 | Richard Scott Struthers reported in an SEC filing no longer being a director |
| Sep 1, 2026 | Richard Scott Struthers reported in an SEC filing no longer being President & CEO |
| Sep 1, 2026 | Matthew K Fust reported in an SEC filing no longer being a director |
| Sep 1, 2026 | Isabel Kalofonos reported in an SEC filing no longer being Chief Commercial Officer |
| Sep 1, 2026 | Coelho Rogerio Vivaldi reported in an SEC filing no longer being a director |
| Sep 1, 2026 | Caren Deardorf reported in an SEC filing no longer being a director |
| Sep 1, 2026 | Camille L Bedrosian reported in an SEC filing no longer being a director |
| Jun 22, 2026 | Wendell Wierenga first on file as a director |
| Apr 1, 2025 | The company announced the departure of Marc Wilson as CFO in an SEC filing |
| Feb 28, 2025 | Tobin Schilke became Chief Financial Officer |
| Dec 16, 2024 | Isabel Kalofonos became Chief Commercial Officer |
| Sep 13, 2024 | The company announced the departure of James Hassard as Chief Commercial Officer in an SEC filing |
| Dec 22, 2023 | Dana Pizzuti listed as Chief Med and Dev Officer (previously Chief Development Officer) in SEC filings |
| Sep 30, 2022 | Dana Pizzuti became Chief Development Officer |
| Mar 21, 2022 | The company announced the departure of Ajay Madan as Chief Development Officer in an SEC filing |
| Mar 11, 2022 | Caren Deardorf became a director |
| Feb 28, 2022 | James Hassard became Chief Commercial Officer |
| Feb 4, 2022 | Marc Wilson listed as CFO (previously CFO and Secretary) in SEC filings |
| Jan 3, 2022 | Coelho Rogerio Vivaldi became a director |
| Oct 15, 2021 | Stephen F. Betz became Chief Scientific Officer |
| Aug 30, 2021 | Jeff E. Knight became Chief Operating Officer |
| Sep 1, 2020 | Camille L Bedrosian became a director |
| Apr 20, 2020 | Perceptive Life Sciences Master Fund Ltd no longer listed as a director in SEC filings |
| Apr 20, 2020 | Perceptive Advisors LLC no longer listed as a director in SEC filings |
| Apr 17, 2020 | Vivo Capital VIII, LLC reported in an SEC filing no longer being a 10% owner |
| Apr 17, 2020 | Vivo Capital Surplus Fund VIII, L.P. reported in an SEC filing no longer being a 10% owner |
| Apr 17, 2020 | Vivo Capital Fund VIII, L.P. reported in an SEC filing no longer being a 10% owner |
| Mar 20, 2020 | Ajay Madan became Chief Development Officer |
| Jul 15, 2019 | Stephanie Okey became a director |
| Jun 25, 2019 | Scott M Rocklage reported in an SEC filing no longer being a 10% owner |
| Jun 25, 2019 | John D Diekman reported in an SEC filing no longer being a 10% owner |
| Jun 25, 2019 | Andrew J. Schwab reported in an SEC filing no longer being a 10% owner |
| Jun 25, 2019 | 5AM Ventures IV, L.P. reported in an SEC filing no longer being a 10% owner |
| Jun 25, 2019 | 5AM Partners IV, LLC reported in an SEC filing no longer being a 10% owner |
| Jun 25, 2019 | 5AM Co-Investors IV, L.P. reported in an SEC filing no longer being a 10% owner |
| Feb 6, 2019 | Versant Ventures V, LLC first on file as a 10% owner |
| Feb 6, 2019 | Versant Ventures V (Canada), L.P. first on file as a 10% owner |
| Jul 20, 2018 | Vivo Opportunity, LLC first on file as a 10% owner |
| Jul 20, 2018 | Vivo Opportunity Fund, L.P. first on file as a 10% owner |
| Jul 17, 2018 | Weston Nichols became a director |
| Jul 17, 2018 | Wendall Wierenga became a director |
| Jul 17, 2018 | Vivo Capital, LLC became a 10% owner |
| Jul 17, 2018 | Vivo Capital VIII, LLC became a 10% owner |
| Jul 17, 2018 | Vivo Capital Surplus Fund VIII, L.P. became a 10% owner |
| Jul 17, 2018 | Vivo Capital Fund VIII, L.P. became a 10% owner |
| Jul 17, 2018 | Versant Venture Capital V, L.P. became a 10% owner |
| Jul 17, 2018 | Versant Venture Capital V (Canada), LP became a 10% owner |
| Jul 17, 2018 | Versant Ophthalmic Affiliates I, L.P. became a 10% owner |
| Jul 17, 2018 | Versant Affiliates Fund V, L.P. became a 10% owner |
| Jul 17, 2018 | Stephen W Kaldor became a director |
| Jul 17, 2018 | Scott M Rocklage became a 10% owner |
| Jul 17, 2018 | Richard Scott Struthers became a director |
| Jul 17, 2018 | Richard Scott Struthers became President & CEO |
| Jul 17, 2018 | Perceptive Life Sciences Master Fund Ltd became a director |
| Jul 17, 2018 | Perceptive Life Sciences Master Fund Ltd became a 10% owner |
| Jul 17, 2018 | Perceptive Advisors LLC became a director |
| Jul 17, 2018 | Perceptive Advisors LLC became a 10% owner |
| Jul 17, 2018 | Orbimed Advisors LLC became a 10% owner |
| Jul 17, 2018 | OrbiMed Capital GP VI LLC became a 10% owner |
| Jul 17, 2018 | Matthew K Fust became a director |
| Jul 17, 2018 | Mason Freeman became a director |
| Jul 17, 2018 | Marc Wilson became CFO and Secretary |
| Jul 17, 2018 | Joseph Edelman became a 10% owner |
| Jul 17, 2018 | John D Diekman became a 10% owner |
| Jul 17, 2018 | Jack Nielsen became a director |
| Jul 17, 2018 | Andrew J. Schwab became a 10% owner |
| Jul 17, 2018 | Alan Seth Krasner became Chief Medical Officer |
| Jul 17, 2018 | 5AM Ventures IV, L.P. became a 10% owner |
| Jul 17, 2018 | 5AM Partners IV, LLC became a 10% owner |
| Jul 17, 2018 | 5AM Co-Investors IV, L.P. became a 10% owner |
Not reported recently (18)
- Alan Seth Krasner · Last reported as Chief Medical Officer in an SEC filing dated Oct 19, 2023
- Joseph Edelman · Last reported as a 10% owner in an SEC filing dated Apr 18, 2022
- Perceptive Advisors LLC · Last reported as a 10% owner in an SEC filing dated Apr 18, 2022
- Perceptive Life Sciences Master Fund Ltd · Last reported as a 10% owner in an SEC filing dated Apr 18, 2022
- Stephen W Kaldor · Last reported as a director in an SEC filing dated Jun 22, 2020
- Vivo Opportunity, LLC · Last reported as a 10% owner in an SEC filing dated Mar 11, 2020
- Vivo Opportunity Fund, L.P. · Last reported as a 10% owner in an SEC filing dated Mar 11, 2020
- Jack Nielsen · Last reported as a director in an SEC filing dated Jun 25, 2019
- Versant Venture Capital V, L.P. · Last reported as a 10% owner in an SEC filing dated Feb 6, 2019
- Versant Ophthalmic Affiliates I, L.P. · Last reported as a 10% owner in an SEC filing dated Feb 6, 2019
- Versant Affiliates Fund V, L.P. · Last reported as a 10% owner in an SEC filing dated Feb 6, 2019
- Versant Venture Capital V (Canada), LP · Last reported as a 10% owner in an SEC filing dated Feb 6, 2019
- Versant Ventures V (Canada), L.P. · Last reported as a 10% owner in an SEC filing dated Feb 6, 2019
- Versant Ventures V, LLC · Last reported as a 10% owner in an SEC filing dated Feb 6, 2019
- Vivo Capital, LLC · Last reported as a 10% owner in an SEC filing dated Jul 20, 2018
- OrbiMed Capital GP VI LLC · Last reported as a 10% owner in an SEC filing dated Jul 17, 2018
- Orbimed Advisors LLC · Last reported as a 10% owner in an SEC filing dated Jul 17, 2018
- Mason Freeman · Last reported as a director in an SEC filing dated Jul 17, 2018
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
CRNX Proposed Insider Sales (Form 144)
Latest: 2026-07-02
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-07-02 | JEFF KNIGHT | Officer | 47,420 | $1.83M | 2026-07-02 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-07-02 | ROGERIO VIVALDI COELHO | Director | 6,000 | $232.1K | 2026-07-02 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-06-17 | STEPHANIE OKEY | Director | 6,900 | $241.5K | 2026-06-17 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-05-04 | JEFF KNIGHT | Officer | 9,485 | $370.1K | 2026-05-04 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-04-14 | JEFF KNIGHT | Officer | 20,900 | $808.0K | 2026-04-14 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-04-13 | JEFF KNIGHT | Officer | 4,434 | $174.9K | 2026-04-13 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-04-08 | JEFF KNIGHT | Officer | 85,163 | $3.27M | 2026-04-08 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-03-18 | DANA PIZZUTI | Officer | 24,756 | $938.0K | 2026-03-18 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-03-16 | Jeff Knight | Officer | 25,113 | $941.5K | 2026-03-16 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-03-16 | Stephen Betz | Officer | 26,525 | $994.4K | 2026-03-16 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
17 ETFs hold CRNX
17 shown · $46.72M total exposure
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.08% | $17.5M | — | 2026-05-31 |
| 2 | NUSC Nuveen ESG Small-Cap ETF | Nport | 0.57% | $7.4M | — | 2026-07-31 |
| 3 | TMSL T. Rowe Price Small-Mid Cap ETF | Nport | 0.21% | $5.8M | — | 2026-06-30 |
| 4 | PRFZ Invesco RAFI US 1500 Small-Mid ETF | Nport | 0.15% | $4.3M | — | 2026-07-31 |
| 5 | SBIO ALPS Medical Breakthroughs ETF | Nport | 2.37% | $3.8M | — | 2026-05-31 |
| 6 | BBP Virtus Biotech Etf | Nport | 3.34% | $3.3M | — | 2026-07-31 |
| 7 | SCHB Schwab U.S. Broad Market ETF | Nport | 0.01% | $2.2M | — | 2026-05-31 |
| 8 | JHSC John Hancock Multifactor Small Cap ETF | Nport | 0.15% | $1.1M | — | 2026-06-30 |
| 9 | ISCB iShares Morningstar Small-Cap ETF | Nport | 0.14% | $386,280 | — | 2026-07-31 |
| 10 | BKSE BNY Mellon US Small Cap Core Equity ETF | Nport | 0.34% | $295,911 | — | 2026-07-31 |
| 11 | ESSC Eventide Small Cap ETF | Nport | 0.62% | $222,163 | — | 2026-07-31 |
| 12 | STXK Strive Small-Cap ETF | Nport | 0.17% | $142,982 | — | 2026-06-30 |
| 13 | MSSM Morgan Stanley Pathway Small-Mid Cap Equity ETF | Nport | 0.02% | $134,130 | — | 2026-05-31 |
| 14 | TILT FlexShares Morningstar US Market Factor Tilt Index Fund | Nport | 0.01% | $118,765 | — | 2026-07-31 |
| 15 | TMED T. Rowe Price Health Care ETF | Nport | 0.26% | $59,722 | — | 2026-06-30 |
| 16 | ACSG American Century Small Cap Growth Insights ETF | Nport | 0.33% | $56,062 | — | 2026-05-31 |
| 17 | TNXT T. Rowe Price Innovation Leaders ETF | Nport | 0.17% | $30,872 | — | 2026-06-30 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-5.04
TTM Revenue
$42.16M
TTM Net Income
$-501.61M
TTM Op. Cash Flow
$-422.51M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $25.12M | $-120.86M | $-1.14 | $-94.19M |
| Q1 '26 | 2026-03-31 | $10.73M | $-127.84M | $-1.23 | $-124.70M |
| Q4 '25 | 2025-12-31 | $6.16M | $-122.81M | $-1.29 | $-92.90M |
| Q3 '25 | 2025-09-30 | $143.00K | $-130.09M | $-1.38 | $-110.72M |
| Q2 '25 | 2025-06-30 | $1.03M | $-115.64M | $-1.23 | $-85.85M |
| Q1 '25 | 2025-03-31 | $361.00K | $-96.77M | $-1.04 | $-88.45M |
| Q4 '24 | 2024-12-31 | $0.00 | $-80.59M | $-0.87 | $-66.87M |
| Q3 '24 | 2024-09-30 | — | $-76.83M | $-0.96 | $-62.82M |
| Q2 '24 | 2024-06-30 | $399.00K | $-74.06M | $-0.94 | $-47.64M |
| Q1 '24 | 2024-03-31 | $640.00K | $-66.93M | $-0.93 | $-52.86M |
| Q4 '23 | 2023-12-31 | $0.00 | $-60.10M | $-0.88 | $-38.52M |
| Q3 '23 | 2023-09-30 | $346.00K | $-57.46M | $-1.01 | $-41.34M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-03
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
—
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-42.1%
ROA
-37.9%
Div Yield
0.00%
FCF Yield
—
Debt/Equity
0.00
Current Ratio
—
Market Cap
$0.00
as of 2026-09-01
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
6.85M
SI % of Float
6.80%
Days to Cover
2.39
Short Vol Ratio
53.2%
Free Float
100.71M
Float %
95.5%
Short interest 2026-08-31 • Short volume 2026-08-31 • Float 2026-05-15